Transplantation and Cellular Therapy最新文献

{"title":"A stem cell-based flow cytometry assay to predict post-transplantation relapse in patients with myelodysplastic syndromes with excess blasts: a prospective study.","authors":"Wei-Bing Wu, Ya-Wen Luo, Si-Qi Li, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Yu-Qian Sun, Meng Lv, Fei-Fei Tang, Xiao-Dong Mo, Xiao-Su Zhao, Kai-Yan Liu, Xiao-Jun Huang, He-Bing Chen, Xiang-Yu Zhao, Ying-Jun Chang","doi":"10.1016/j.jtct.2026.10.016","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.10.016","url":null,"abstract":"<p><strong>Background: </strong>We aim to investigate whether the myelodysplastic syndrome stem cell (MDS-SC)-based assay could be used to predict relapse and survival after treatment in patients with MDS with excess blasts (MDS-EB).</p><p><strong>Methods: </strong>A total of 143 cases receiving allografting were prospectively enrolled. A single-cell proteogenomic technique was used to evaluate the characteristics of CD34⁺ MDS subsets. These cells were detected using multiparameter flow cytometry (MFC) at diagnosis and post-treatment.</p><p><strong>Results: </strong>The phenotypically defined (PD) CD34⁺CD38^-cocktail⁺ (CD56/CD22/CD11b/CD7/Tim-3/CLL-1) MDS-SCs exhibited greater stemness and quiescence than PD CD34⁺CD38^-MDS-SCs with other immunophenotypes. A high level of pre-transplantation PD CD34⁺CD38^-cocktail⁺MDS-SCs (≥0.1064%) independently predicted 3-year cumulative incidence of relapse (CIR, P<0.001). No association of pre-transplantation traditional MFC-based MDS cells with relapse was observed. Patients with positive post-transplantation PD CD34⁺CD38^-cocktail⁺MDS-SCs (≥0.0081%) experienced a higher 3-year CIR (40.4% vs. 6.5%, P<0.001) and lower disease-free survival (DFS, 57.4% vs. 85.1%, P<0.001) than those negative cases. Multivariate analysis revealed that positive post-transplantation PD CD34⁺CD38^-cocktail⁺MDS-SCs independently predicted CIR (P<0.001) and DFS (P<0.001). Patients with post-transplantation traditional MFC-MRD positivity also had a higher CIR (60.0% vs. 12.8%, P<0.001) and lower DFS (40.0% vs. 80.2%, P<0.001) than those negative cases. The MDS-SC-based assay has higher sensitivity and C-index for MRD detection than the traditional MFC method.</p><p><strong>Conclusion: </strong>Our data suggest the potential superiority of the PD MDS-SC-based assay over the traditional MFC method for outcome prediction in MDS-EB patients.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients\".","authors":"Lilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, Kimberly Ward, Jamie Chau, Christopher Otteni, Denise Kalos, Johannes Ali, MacLean S Hall, Matthew Beatty, Olga V Klinkova, Mohammed E Alomar, Eric E Gaskill, Rebecca M Gonzalez, Hanna Bailey, Michael Yu, Nam Tran, Lianicet Rodriguez-Alfonso, Ella Vieira, Karla Adams, Michael Jain, Frederick L Locke, Jobelle Baldonado, Matthew C Perez, John Mullinax, Jonathan S Zager, Ricardo Gonzalez, Vernon K Sondak, Joseph Markowitz, Andrew S Brohl, Zeynep Eroglu, Ahmad A Tarhini, Nikhil I Khushalani, James J Mulé, Amod A Sarnaik, Shari Pilon-Thomas","doi":"10.1016/j.jtct.2026.09.032","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.09.032","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma\" Transplantation and Cellular Therapy (2026).","authors":"Lilit Karapetyan, Justin Moser, Barbara T Ma, Christopher Otteni, Elizabeth Cathcart, Kimberly Loo, Jay Jacoby, Jamie K Chau, James W Smithy, Nikhil Nayee, Anna C Pavlick, Ahmed Tawashi, Amritha Seshaadri, Min Yi, Friedrich Graf Finckenstein, Brian Gastman, Alexander N Shoushtari","doi":"10.1016/j.jtct.2026.09.031","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.09.031","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress of T Cell Metabolism in Graft-Versus-Host Disease.","authors":"Yihan Ding, Bo Hu, Chengwan Zhang","doi":"10.1016/j.jtct.2026.10.010","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.10.010","url":null,"abstract":"<p><p>Graft-versus-host disease (GVHD) is a common and severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is caused by activated alloreactive T cells that attack recipient target organs and represents a major cause of non-relapse mortality, thereby limiting the efficacy of allo-HSCT. Persistent alloantigen stimulation can induce metabolic dysregulation in T cells, involving pathways such as glycolysis, lipid metabolism, amino acid metabolism, nucleotide metabolism, and mitochondrial oxidative phosphorylation. Given the close relationship between T cell metabolism and T cell activation, differentiation, and effector functions, targeted modulation of T cell metabolism may emerge as a novel strategy for the prevention and treatment of GVHD. This review summarizes the roles of major T cell metabolic pathways in the pathogenesis and progression of GVHD with the aim of informing future mechanistic studies and therapeutic strategies.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.","authors":"Natalia Tijaro Ovalle, Andrew Lin, Nancy Cruz Sitner, Ryan Schofield, Brenden Bready, Mithat Gonen, A Zara Herskovits, Ross S Firestone, Hamza Hashmi, Hani Hassoun, Malin Hultcrantz, Neha S Korde, Alexander M Lesokhin, Kylee Maclachlan, Sham Mailankody, Francesco Maura, Maximillian Merz, Sridevi Rajeeve, Urvi A Shah, Caryln Rose Tan, Saad Z Usmani, Miguel-Angel Perales, Parastoo B Dahi, Eric M Jurgens, David J Chung, Michael Scordo, Heather J Landau, Sergio A Giralt, Gunjan L Shah","doi":"10.1016/j.jtct.2026.10.015","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.10.015","url":null,"abstract":"<p><p>High-dose therapy (HDT) with melphalan followed by autologous hematopoietic cell transplantation (AHCT) remains standard for multiple myeloma (MM) consolidation. However, body surface area-based dosing results in interpatient variability in exposure, which may affect efficacy and toxicity. We retrospectively studied patients with MM who underwent AHCT and had serial melphalan concentrations measured after HDT. Melphalan area under the concentration-time curve (AUC) was calculated using non-compartmental analysis (NCA) and estimated using a two-compartment population pharmacokinetic (pop PK) model. 148 patients were included; median follow-up was 6.3 years. Median melphalan AUC was 12.7 mg*h/L by NCA and 14.0 mg*h/L by pop PK, with significant correlation between methods (r=0.64, P<0.001). Patients with NCA AUC equal to or above the median had superior 12- and 24-month progression-free survival compared with those below the median (75% vs 62% and 60% vs 44%, P=0.019). Pop PK AUC showed a similar trend (76% vs 61% and 57% vs 47%, P=0.11). Overall survival and non-relapse mortality did not differ by exposure. Higher exposure was associated with longer hospitalization, neutropenic fever days and more CTCAE v5.0 grade ≥3 nonhematologic toxicities. Higher pop PK AUC was associated with overall response at day 100 (OR 2.94, 95% CI, 1.04-9.60, P=0.041). Higher exposure by NCA and pop PK was also associated with day 100 measurable residual disease negativity (OR 0.47, 95% CI 0.23-0.96, P=0.038 and OR 0.40, 95% CI 0.19-0.81, P=0.011, respectively). These findings support prospective evaluation of pop PK-guided melphalan dosing to define an exposure range that optimizes efficacy while limiting toxicity.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Placental-Derived Products for Corneal Regeneration: Applications of Amniotic Membrane, Cord Blood Serum, and Stem Cells: A Review\".","authors":"Huizhen Jia","doi":"10.1016/j.jtct.2026.09.053","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.09.053","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Prophylactic Steroids on CAR T-cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.","authors":"Alma Habib, Youssef Youssef, Rina Li Welkie, Jacob Butman, David A Bond, Yazeed Sawalha, Audrey Sigmund, John C Reneau, Lapo Alinari, No-Joon Song, Wing Chan, Jordan Krull, Mark P Rubinstein, Walter Hanel, Beth Christian, Robert A Baiocchi, Kami Maddocks, Jonathan Brammer, Gabriela Sanchez-Pettito, Polina Shindiapina, Hannah Choe, Jiasheng Wang, Timothy J Voorhees, Aharon G Freud, Sumithira Vasu, Sarah Wall, Marcos de Lima, Nathan Denlinger","doi":"10.1016/j.jtct.2026.09.047","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.09.047","url":null,"abstract":"<p><strong>Background: </strong>Anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). However, toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain significant. Prophylactic corticosteroid use increased after cohort 6 of ZUMA-1, which suggested reduced severe CRS and ICANS, although the lack of a comparator arm limits interpretation.</p><p><strong>Objective: </strong>To evaluate the impact of steroid prophylaxis on outcomes and toxicities in a real-world setting.</p><p><strong>Study design: </strong>We conducted a retrospective, single-institution analysis of adults (≥18 years) with R/R NHL treated with CD28 costimulated axicabtagene ciloleucel (axi-cel) or brexucabtagene autoleucel (brexu-cel) at The Ohio State University (2018-2023). All patients received steroid prophylaxis (dexamethasone 10 mg daily × 3 from infusion day). Outcomes including toxicities (CRS, ICANS) and response rates, survival outcomes, and hazard ratios were compared using logistic regression, log-rank test, and Cox model.</p><p><strong>Results: </strong>137 patients received CAR-T (axi-cel n=118, brexu-cel n=19); 27.0% received steroid prophylaxis (PPX). Baseline characteristics were similar between groups, although primary refractory disease differed. CRS and ICANS prevalence did not significantly differ between cohorts. Any-grade CRS occurred in 97.3% of patients with PPX vs 88.0% with no PPX (p=0.13), with grade 3-4 CRS in 2.7% vs 12.0% (p=0.13). ICANS occurred in 75.7% vs 68.0% (p=0.38), with grade 3-4 ICANS in 24.3% vs 32.0% (p=0.38). Median time to CRS onset was delayed in the PPX group (4 vs 3 days, p<0.01), with no difference in ICANS onset. Overall response rates (ORR) were 75.7% vs 69.0% (p=0.44); complete response rates (CRR) were 62.2% vs 54.0% (p=0.39). OS and PFS did not differ.</p><p><strong>Conclusion: </strong>Prophylactic corticosteroids did not impact CRS, ICANS, response rates, or survival. Although CRS onset may be modestly delayed, these findings do not support routine steroid prophylaxis in CAR-T-treated NHL patients.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming Primary Graft Failure in Pediatric Allogeneic HSCT: Insights from Ten Centers of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).","authors":"Mariona Morell Daniel, Melissa Panesso Romero, Maria Isabel Benítez Carabante, Sara Vinagre Enríquez, Mercedes Plaza Forniels, Ivan López Torija, Andrea Urtasun Erburu, David Bueno, Graciela Gómez, Carolina Fuentes, Jose Maria Pérez Hurtado, Jaime Verdú Amorós, Santiago Pérez Hoyos, M Luz Uría Oficialdegui, Laura Alonso García, Cristina Diaz-de-Heredia","doi":"10.1016/j.jtct.2026.10.017","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.10.017","url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for malignant and non-malignant diseases; however, primary graft failure (GF) is a life-threatening complication, particularly with the increasing use of alternative donors and reduced-intensity conditioning (RIC) strategies. Data on outcomes and optimal management-especially in the pediatric population-remain limited and heterogeneous.</p><p><strong>Objectives: </strong>The primary endpoint was overall survival (OS) in patients with primary GF. Secondary endpoints included OS in patients with primary GF after salvage HSCT and the evaluation of risk factors associated with engraftment and survival.</p><p><strong>Methods: </strong>We conducted a multicenter, retrospective, observational study including pediatric patients (<18 years) diagnosed with primary GF after a first allogeneic HSCT between January 2011 and July 2022 across 10 Spanish pediatric transplant centers.</p><p><strong>Results: </strong>A total of 1561 allogeneic HSCTs were performed. Fifty-seven patients developed primary GF, yielding an overall incidence of 3.65%, which was higher among transplants with donors with HLA disparities. One-year OS for patients with primary GF was 73%. Over 90% of patients underwent salvage HSCT, with 74% achieving engraftment. No risk factors for engraftment were identified. One-year OS after the second HSCT was 71%. Achieving engraftment after the second transplant was the only factor significantly associated with survival (1-year OS, 81% [95% CI, 65-90] vs. 43% [95% CI, 17-66]; p < 0.001). No other clinical or transplant-related variables showed significant associations with survival.</p><p><strong>Conclusions: </strong>GF remains a major challenge and continues to limit the overall success of HSCT. The majority of patients underwent a second transplant, with engraftment achieved in 74% of patients. Overall survival was 68% at 2 years after the first transplant. The frequent use of RIC regimens including fludarabine and serotherapy in patients undergoing retransplantation reflects a commonly adopted clinical practice, although no specific conditioning regimen was significantly associated with engraftment or survival.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endorsed but unevenly embedded: Implementing UK pre-transplant psychological assessment guidelines - a UK-wide service evaluation.","authors":"Lewis MacDonald-Winship, Anna Lagerdahl, Chloe Grimmett, Mike Rennoldson, Hermioni L Amonoo, Laura J Miller, Michael Baliousis","doi":"10.1016/j.jtct.2026.10.003","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.10.003","url":null,"abstract":"<p><p>In 2024, Anthony Nolan in the UK published the first guidance on pre-transplant psychological assessment for adults undergoing HSCT, endorsed by the Association of Clinical Psychologists UK. It recommends six components: embedded specialist support, timing, routine referral, psychosocial assessment, recording and sharing findings, and follow-up support. Nothing is yet known about whether transplant services have taken it up and we know guidelines usually need work to be implemented. We surveyed 32 UK HSCT professionals to find out which components they report in their services, and to identify what is helping or hindering the guidance becoming routine work, using implementation theory. Two findings seem worth the journal's attention. First, the pattern of adoption is uneven in a specific and reparable way: respondents commonly reported embedded psychology and guideline-informed assessment, but reported routine referral, followup, and the recording and sharing of findings much less often. Referral typically required a distress-screening threshold rather than being offered routinely, which is not what the guidance suggests. Second, and unusually for a study of guideline uptake, the shortfall does not appear to sit with clinicians. Using Normalisation Process Theory and the NoMAD instrument, we found strong individual understanding, perceived benefit and willingness to act, alongside weak shared cross-disciplinary understanding, insufficient resource, and unclear ownership of documentation. The implication for transplant centres is practical: protected psychological capacity is necessary but will not on its own produce routine assessment without agreed MDT processes for who records findings and where.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient‑Reported Late Effects in Allogeneic Hematopoietic Stem Cell Transplantation Survivorship: A Nationwide Population‑Based Study.","authors":"Mette Schaufuss Engedal, Kristina Nørskov, Anders Tolver, Lea Brandt Kristensen, Astrid Lindman, Gitte Olesen, Brian Thomas Kornblit, Christoffer Johansen, Mary Jarden","doi":"10.1016/j.jtct.2026.09.052","DOIUrl":"https://doi.org/10.1016/j.jtct.2026.09.052","url":null,"abstract":"<p><strong>Background: </strong>Survivorship after allogeneic hematopoietic stem‑cell transplantation (allo‑HCT) is associated with late effects and chronic graft‑versus‑host disease (cGVHD), but population‑level data on patient‑reported outcomes remain limited.</p><p><strong>Objective: </strong>To characterize the multidimensional burden of patient-reported late effects in a nationwide cohort of allo-HCT survivors, compare health-related quality of life (HRQOL) with Danish population reference values, and identify symptoms and functional impairments exceeding thresholds for clinical importance.</p><p><strong>Study design: </strong>In this nationwide, population-based cross-sectional study, adult allo-HCT survivors transplanted in Denmark between 1973 and 2024 were identified through transplant databases and registry linkage. Participants completed the EORTC Survivorship Questionnaire (QLQ-SURV100). QLQ-C30-equivalent HRQOL scores were compared with age- and sex-stratified Danish population reference values, and thresholds for clinical importance were applied.</p><p><strong>Results: </strong>Of 1333 eligible survivors, 895 participated (67%). Median age was 64 years (range, 21-84), and median time since transplantation was 7 years (range, 0-44). Participants reported a mean of 18 concurrent symptoms, including 8 of moderate-to-high severity; only 1% reported none. Negative health outlook (93%) and fatigue (90%) were the most prevalent late effects. Overall, 91% reported low or moderate sexual functioning, and sexual problems showed the highest severity. Among participants aged ≤67 years, 45% were not working, and loss of income was reported by 54% overall. Participants reported poorer HRQOL than population reference values, and 38% exceeded thresholds for clinical importance in at least 5 domains.</p><p><strong>Conclusion: </strong>Allo-HCT survivorship is characterized by multiple concurrent symptoms and impairments, demonstrating a substantial population-level burden with implications for long-term survivorship care.</p><p><strong>Registration: </strong>ClinicalTrials.gov, NCT06277479.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}